On November 25, 2020 Hamlet Pharma AB reported its successfully secured patent protection in Europe for its lead clinical candidate, Alpha1H (Press release, HAMLET Pharma, NOV 25, 2020, View Source;utm_medium=rss&utm_campaign=alpha1h-patent-granted-in-europe [SID1234574599]). This protection is granted as European patent number EP 3618848 B1, which will remain valid until May 14, 2038.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Alpha1H is currently used in clinical trials in patients with bladder cancer. With this patent, Hamlet Pharma AB continues to expand it’s intellectual property portfolio in areas where its key products show benefit. Following this success at the European Patent Office, where the claims of EP 3618848 B1 were readily accepted for grant, Hamlet Pharma AB plans to seek equivalent protection in further key countries around the world.

"This demonstrates the uniqueness of the innovation and the opportunities Alpha1H may offer cancer patients" says Catharina Svanborg, CMO and chairman of the board of Hamlet Pharma Ltd.

"Alpha1H is our lead drug candidate and this is an important milestone to secure long-term protection in Europe" says Mats Persson, CEO of Hamlet Pharma Ltd.